Media coverage about Nevro Corp. (NYSE:NVRO) has trended somewhat positive on Saturday, according to Accern. The research firm identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Nevro Corp. earned a news sentiment score of 0.19 on Accern’s scale. Accern also assigned news stories about the medical equipment provider an impact score of 45.7745111778043 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news stories that may have effected Accern Sentiment’s analysis:
- Nevro Corp. (NVRO) Expected to Post Quarterly Sales of $79.51 Million (americanbankingnews.com)
- Dynamic Technology Lab Private Ltd Marginally Increases Its Stake in Nevro Corp. (NVRO) – First News 24 (firstnewspaper24.com)
- From A Very Different Angle: Nevro Corp. (NVRO), MDU Resources Group, Inc. (MDU) – AllStockNews (allstocknews.com)
- Nevro Corp. (NYSE:NVRO) Trading Up – Insiders Selling, Short Interest Growing (highlightpress.com)
- Headed For a Pullback? Share Update on Nevro Corp (NVRO) – Sparta Review (spartareview.com)
Shares of Nevro Corp. (NYSE:NVRO) opened at 84.01 on Friday. The firm has a 50 day moving average price of $83.73 and a 200 day moving average price of $85.18. Nevro Corp. has a 52 week low of $65.82 and a 52 week high of $106.93. The company’s market capitalization is $2.47 billion.
Nevro Corp. (NYSE:NVRO) last posted its quarterly earnings results on Monday, August 7th. The medical equipment provider reported ($0.40) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.29) by $0.11. The business had revenue of $78.02 million for the quarter, compared to the consensus estimate of $77.75 million. Nevro Corp. had a negative net margin of 14.33% and a negative return on equity of 16.25%. Nevro Corp.’s revenue was up 40.8% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.31) earnings per share. Equities analysts forecast that Nevro Corp. will post ($1.16) EPS for the current year.
A number of brokerages recently commented on NVRO. Zacks Investment Research lowered Nevro Corp. from a “buy” rating to a “hold” rating in a report on Friday, August 11th. Northland Securities reiterated a “buy” rating and set a $96.00 price target on shares of Nevro Corp. in a report on Tuesday, August 8th. Morgan Stanley lifted their price target on Nevro Corp. from $87.00 to $95.00 and gave the stock an “overweight” rating in a report on Tuesday, August 8th. BidaskClub lowered Nevro Corp. from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Finally, Canaccord Genuity reiterated a “buy” rating and set a $120.00 price target on shares of Nevro Corp. in a report on Wednesday, July 5th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $100.57.
In other news, Director Wilfred E. Jaeger sold 79,657 shares of the firm’s stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $82.74, for a total transaction of $6,590,820.18. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Andrew H. Galligan sold 7,000 shares of the firm’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $82.31, for a total value of $576,170.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 141,577 shares of company stock worth $11,696,551. Insiders own 12.10% of the company’s stock.
Nevro Corp. Company Profile
Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Receive News & Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related companies with MarketBeat.com's FREE daily email newsletter.